Alkem Labs recommends ₹10 dividend; AGM on Aug 27; Re-appoints Madhurima Singh
Alkem Laboratories approved Q4 FY26 results and recommended a final dividend of ₹10 per share. The 52nd AGM is set for August 27, 2026, with August 7, 2026, as the record date for dividend payment. Mrs. Madhurima Singh was re-appointed as Executive Director for five years from December 20, 2026.
The dividend recommendation and director re-appointment are significant corporate actions that can impact shareholder value and company governance.
The announcement is positive due to the recommendation of a final dividend and the re-appointment of an executive director, indicating stability and shareholder returns.
Alkem Laboratories Limited has announced the outcome of its Board Meeting held on May 28, 2026. The Board has approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2026.
The Board recommended a final dividend of ₹10 per equity share of ₹2 each for the financial year ended March 31, 2026. This recommendation is subject to the approval of shareholders at the upcoming Annual General Meeting (AGM).
The 52nd AGM of the Company is scheduled to be held on August 27, 2026, with a cut-off date of August 20, 2026, for the AGM. Furthermore, August 7, 2026, has been fixed as the record date for the payment of the final dividend. If declared by shareholders, the dividend will be paid on or after September 1, 2026.
In a significant management update, the Board has approved the re-appointment of Mrs. Madhurima Singh as an Executive Director for a term of five consecutive years, effective from December 20, 2026, to December 19, 2031. This re-appointment is based on the recommendations of the Nomination and Remuneration Committee and the Audit Committee and is subject to shareholder approval at the ensuing AGM.
The company also confirmed that the auditors have expressed an unmodified opinion in their Audit Reports on the financial results. The Board meeting commenced at 11:20 a.m. and concluded at 1:15 p.m.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.